Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
Mark J. Mulligan(NYU Langone Health), Kirsten E. Lyke(University of Maryland, Baltimore), Nicholas Kitchin(Pfizer (United Kingdom)), Judith Absalon(Pfizer (United States)), Alejandra Gurtman(Pfizer (United States)), Stephen Lockhart(Pfizer (United Kingdom)), Kathleen M. Neuzil(University of Maryland, Baltimore), Vanessa Raabe(NYU Langone Health), Ruth Bailey(Pfizer (United Kingdom)), Kena A. Swanson(Pfizer (United States)), Ping Li(Pfizer (United States)), Kenneth Koury(Pfizer (United States)), Warren V. Kalina(Pfizer (United States)), David Cooper(Pfizer (United States)), Camila R. Fontes-Garfias(The University of Texas Medical Branch at Galveston), Pei‐Yong Shi(The University of Texas Medical Branch at Galveston), Özlem Türeci(BioNTech (Germany)), Kristin R. Tompkins(Pfizer (United States)), Edward E. Walsh(Rochester General Hospital), Robert W. Frenck(Cincinnati Children's Hospital Medical Center), Ann R. Falsey(Rochester General Hospital), Philip R. Dormitzer(Pfizer (United States)), William C. Gruber(Pfizer (United States)), Uğur Şahin(BioNTech (Germany)), Kathrin U. Jansen(Pfizer (United States))
Cited by 1,584Open Access